Does Erythropoietin Improve Outcome in Very Preterm Infants?

Completed

Phase 2 Results N/A

Summary of Purpose

The main goal of this trial is to investigate whether early administration of human erythropoietin (EPO) in very preterm infants improves neurodevelopmental outcome at 24 months corrected age. This study is designed as randomized, double-masked, placebo controlled multicenter study involving at least 420 patients.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 23 February 2015.

1 Jan 2006 18 Dec 2006 1 Mar 2012 1 Mar 2012 1 Feb 2015 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Prevention
  • Endpoint: Bio-availability Study
  • Intervention: Parallel Assignment

Contacts